Savina Pharma
Leveraging Our Platform Technology to Treat Immunoinflammatory Disease
Savina Pharma
Leveraging Our Platform Technology to Treat Immunoinflammatory Disease
Savina Pharma is a early-stage biopharma company focused on developing our lead candidate, SP-101, for the treatment of rheumatoid arthritis. Founded in 2025 by industry-leading area experts and experienced biotech entrepreneurs after acquiring the platform and lead drug candidate technology and intellectual property from Chariton Pharmaceuticals. We are a drug development company focused on bringing to market new therapies to treat rheumatoid arthritis and other immunoinflammatory diseases. Despite advancement in biologics and other therapies to treat rheumatoid arthritis, there remains major unmet need in this debilitating disease.
Our mission is to relieve the suffering associated with rheumatoid arthritis using our proprietary polymer pro-drug technology to develop a reformulation of dexamethasone, SP-101, with optimized delivery of the active ingredient only to sites of inflammation rendering it free of the dose and duration of use limiting systemic side effects. Through a previous pharmaceutical company partnership, SP-101 has undergone considerable early development that has made it first in class to achieve critical, and industry first, benchmarks of development.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.